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 Abstract  
Objective: To determine pharmacokinetic and pharmacodynamic properties of oral dexamethasone 
solution and powder compared to intravenous dexamethasone solution in healthy horses.  
Animals: 6 horses, 13-27 years if age, 385-630 kg  
Procedures:   In a randomized, cross-over block design six healthy adult horses each received the 
following treatments 1) dexamethasone solution IV 0.05 mg/kg, 2) dexamethasone solution orally 
(PO) 0.05 mg/kg, and 3) dexamethasone powder PO 0.05 mg/kg all in the fed and fasted state.  Each 
horse acted as an untreated control as secretion of cortisol was monitored for normal circadian 
rhythm. Quantification of plasma dexamethasone concentration and serum cortisol activity was 
determined by LC/MS and chemiluminescent enzyme immunoassay, respectively. 
Results: Each horse exhibited a circadian rhythm in cortisol secretion; however there was variation 
present between each horse.  Mean cortisol concentrations at 6:00 AM and 8:00 AM were 
significantly higher than concentrations at 8:00 PM and 10:00PM.  Cortisol concentrations were 
significantly less than base-line starting 1 hour post-administration of dexamethasone through 72 
hours for the fasted treatment groups, and 2 hours through 48 hours for the fed groups.  
Pharmacokinetic modeling resulted in a two compartment model for the IV administration with 
elimination from the central compartment, and a one compartment model for orally administered 
dexamethasone.  Oral, fasted, compounded powder achieved a significantly higher maximum 
concentration (Cmax) than both fasted and fed oral dexamethasone solutions.   The AUC0
inf for the 
orally administered compounded powder was significantly different when comparing fasted versus 
fed treatment groups.  Bioavailability ranged between 33% and 70% among treatment groups, but 
due to the high variability there was not a significant difference. 
Conclusions and Clinical Relevance: Hospitalization of the horses did not have an effect on their 
circadian rhythm of cortisol secretion.  Oral and intravenous administration of dexamethasone 
 resulted in adrenal suppression with cortisol concentrations returning to base-line 48-72 hours post-
administration.  Although bioavailability was variable cortisol suppression was similar among all 
treatment groups.  The variability in oral absorption will need to be taken in to account for oral 
dosing of dexamethasone. 
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CHAPTER 1 - Literature Review  
 
Adrenal Gland 
   
 Anatomy and Function  
 
The adrenal glands in the horse are located at the medial-cranial poles of both the left and 
right kidney.1,2  They are approximately 7-8 cm long, 3cm wide, 1.5 cm thick, and weigh 
approximately 15-20 grams.2  The adrenal artery branches off of the aorta or renal artery to provide 
blood supply to the adrenal glands.2  Sympathetic nerve fibers from the splanchnic nerve provide 
innervation to the adrenal glands.2  Each adrenal gland is comprised of an adrenal medulla and an 
adrenal cortex.  The adrenal medulla is centrally located and accounts for approximately 20% of the 
gland.1  The adrenal medulla is closely related to the sympathetic nervous system as epinephrine and 
norepinephrine are released into circulation from the adrenal medulla in response to sympathetic 
stimulation.1,2  The peripherally located adrenal cortex is further divided into three distinct zones: 
zona glomerulosa, zona fasciculata, and zona reticularis.1  The zona glomerulosa is composed of a 
thin layer of cells that lie just beneath the capsule of the adrenal gland.1  The zona glomerulosa 
comprises approximately 15% of the adrenal cortex, and is critical for secreting aldosterone in 
response to the renin-angiotensin system and changes in the osmolality of extracellular fluid.1  The 
zona fasciculata lies just deep to the zona glomerulosa and comprises approximately 75 percent of 
the adrenal cortex.1  Major hormones secreted from the zona fasciculata include cortisol and 
corticosterone in response to adrenocorticotropic hormone (ACTH) stimulation, in addition small 
amounts of androgens and estrogens are also secreted from the zona fasciculata.1,2  The deepest layer 
of the adrenal cortex is the zona reticularis which is responsible for the secretion of the androgens 
dehydroepiandrosterone and androstenedione.1  In addition, small amounts of estrogens and 
glucocorticoids are secreted from the zona reticularis.1 
Glucocorticoids 
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Background 
 
The primary endogenous glucocorticoid produced is cortisol which accounts for 
approximately 95% of glucocorticoid activity.1,3  Corticosterone accounts for approximately 4% of 
glucocorticoid activity.1,3  Cortisone has also been reported to be isolated from horses in small 
quantities.4  The majority (80-95%) of cortisol in circulation is found in the inactive form bound to 
transcortin, a corticosteroid-binding globulin1,5.  A smaller concentration can be found bound to 
albumin, and it is this albumin-bound portion that is able to diffuse extravascularly5.  Plasma cortisol 
concentrations have been quantified using a variety of assays including radiostereoassay, thin layer 
chromatography, ultraviolet absorption, fluorescence, high pressure liquid chromatography, and 
radioimmunoassay.  The half-life of cortisol has been reported to be 80 minutes in horses which is 
consistent with the half-life found in humans.1,3  However, in another study performed by Slone et al, 
the half-life was found to be 2.1 ± 0.6 hours in bilaterally adrenalectomized horses.6  In 1966, 
Zolovick et al, reported that mean combined cortisol and corticosterone concentrations in the horse 
ranged from 219.0 µg/dL to 395.3 µg/dL.4  Since then various other studies, however have found 
either cortisol and corticosterone in combination or cortisol alone to measure 5.12 µg/dL, 1.37 µg/dL, 
4.35 µg/dL, and 5.9 µg/dL.7-10  Hoffsis et al, found mean cortisol concentrations to be elevated in 
cases of acute illness (shock, colic, fracture, dystocia, and anesthesia) ranging from 10.51 µg/dL to 
16.4 µg/dL compared to 5.12 µg/dL in healthy horses.11  Common synthetic analogues of cortisol 
used today in equine patients include dexamethasone, prednisolone, prednisone, methylprednisolone, 
triamcinolone, beclomethasone, and fluticasone.  These synthetic glucocorticoids do not compete 
with endogenous cortisol for binding sites on transcortin and are more readily able to diffuse 
extravascullarly.5  In addition, they have longer plasma and biological half-lives than cortisol.5  
Furthermore, synthetic glucocorticoids have increased anti-inflammatory potency when compared to 
endogenous cortisol.  Prednisolone, methylpredisolone, and triamcinolone are 3-5 times more potent, 
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and dexamethasone and betamethasone are 20-30 times more potent than cortisol.1,5  Table 1.1 lists 
cortisol and synthetic analogues with their anti-inflammatory potency and plasma and biological 
half-lives.1,5  Because of these properties the synthetic glucocorticoids are able to have more rapid 
and prolonged biological effects than cortisol.5  Melby reports that it is possible to approximate the 
duration of therapeutic effects of synthetic and natural glucocorticoids by evaluating the 
hypothalamic pituitary-adrenal suppressing activity.5  
Table 1.1: Anti-inflammatory potencies and plasma and biological 
half-lives of cortisol and its synthetic analogues5
 
 Anti-inflammatory 
potency 
Plasma half-life 
(min) 
 
Biological half life 
(hr) 
 Cortisol 1   90 8-12 
Prednisolone 3-5 200 or greater 12-36 
Methylprednisolone 3-5 200 or greater 12-36 
Triamcinolone 3-5 200 or greater 12-36 
Betamethasone 20-30 300 or greater 36-54 
Dexamethasone 20-30 300 or greater 36-54 
  
Chemical Composition 
Glucocorticoids (GC) are synthesized from cholesterol within the adrenal cortex.1  
Cholesterol enters the mitochondria where it is cleaved by cholesterol desmolase, and forms 
pregnenolone.1  Within the mitochondria or endoplasmic reticulum pregnenolone is catalyzed by 
specific enzymes within various pathways resultling in the formation of aldosterone, cortisol, or 
androgens.1  Both ACTH and angiotensin II hasten the conversion of cholesterol to pregnenolone.1 
Glucocorticoids have a four ring, 21-carbon structure (figure 1.1).  The A ring contains a ketone 
group at C3 and a double bond at C4,5 which are essential for the anti-inflammatory properties of 
glucocorticoids.12  It is the double bond associated with C1,2 that allows for an increase in 
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glucocorticoid activity without increased mineralocorticoid activity.12  The C ring contains a 
hydroxyl group located at C11 that is critical for the anti-inflammatory activity of glucocorticoids, 
but again does not increase mineralocorticoid activity.12  Inactive forms of glucocorticoids contain a 
ketone group instead of a hydroxyl group at C11.  Following conversion to a hydroxyl group at the 
C11 position glucocorticoid activity is initiated.12  Although synthetic glucocorticoids have primarily 
glucocorticoid activity; prednisolone, prednisone, methylprednisolone, cortisone, and isoflupredone 
have been shown to have mineralocorticoid properties as well.1,13,14  
 
Figure 1.1: Chemical composition of dexamethasone 
 
Metabolic Functions 
Endogenous glucocorticoids secreted by the zona fasciculata have numerous metabolic 
functions that are essential for host health.1,5,15,16  The primary glucocorticoid secreted from the 
adrenal cortex is cortisol composing 95% of glucocorticoid activity.1  Glucocorticoids (primarily 
cortisol) gained their name for their ability to stimulate gluconeogenesis and maintain blood glucose 
concentrations.1,5,15  Two main mechanisms of cortisol that stimulate gluconeogenesis are: 1) gene 
DNA transcription is activated by cortisol in the hepatocyte nuclei that leads to the production of 
proteins required for gluconeogenesis, and 2) cortisol enhances the mobilization of amino acids 
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making them readily available for gluconeogenesis.1,15  In addition to increasing gluconeogenesis, 
cortisol decreases the rate at which glucose is utilized in the body, reducing the sensitivity of cells to 
insulin.1,5,15,17  Peripheral insulin resistance is advantageous to the host because this maintains the 
availability of glucose for the central nervous system and heart, which are organs that do not require 
insulin for uptake of glucose.  The mechanisms through which these mechanisms occur are not 
completely understood.  Cortisol has been shown to decrease protein synthesis and increase 
catabolism of protein in extra-hepatic tissues.1,5   Since cortisol suppresses the transport of amino 
acids into extra-hepatic tissues, and the catabolic effects of cortisol results in release of amino acids 
from these extra-hepatic tissues amino acids are available for enhanced hepatic protein production.1,5  
Cortisol also promotes lipolysis through the mobilization of fatty acids from adipose tissue.1  Again 
the mechanisms by which cortisol regulates these metabolic functions remains to be fully elucidated. 
Stress  
Cortisol secretion is significantly increased during stressful and painful situations.  There are 
several types of stress that have been related to cortisol secretion including: trauma, infection, intense 
heat or cold, injection of sympathomimetic drugs, surgery, restraint, and debilitating disease.1,15  It is 
well understood that enhanced secretion of ACTH from the anterior pituitary increases the secretion 
of cortisol.1,15  However, the benefit of the enhanced secretion is not well understood.  Several 
theories have been proposed including the mobilization of amino acids and fats making them 
accessible for energy and synthesis of other compounds.1,15     
Anti-inflammatory and Immunosuppressive Effects 
The anti-inflammatory and immunosuppressive properties of glucocorticoids are the primary 
reason for their clinical use.  Cortisone, the inactive form of cortisol, was first isolated in 1936, and 
Reichstein first synthesized cortisol in 1938.18  In 1950, Hench and coworkers received the Nobel 
Prize for describing the beneficial effects of exogenous glucocorticoids for the treatment of 
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osteoarthritis in human patients.12,18,19  Glucocorticoids are used for a variety of conditions in equine 
patients including: recurrent airway obstruction, inflammatory airway disease, dermatitis, purpura 
hemorrhagica, neurological disease and trauma, shock, arthritis, neoplasia, and immune-mediated 
conditions.15,20-22   
Glucocorticoids suppress inflammation and exert immunosuppressive effects through a variety of 
mechanisms.   Prior to the current understanding of the mechanisms associated with the anti-
inflammatory effects of glucocorticoids certain cellular characteristics were recognized.  
Glucocorticoids have been recognized to have multiple properties in preventing inflammation such 
as: 1) stabilization of lysosomal membranes; 2) decreasing the permeability of capillary walls; 3) 
suppression of migration of white blood cells into areas of inflammation and decreased phagocytosis 
of damaged cells; 4) immunosuppression associated with decreased T-lymphocyte 
production/survival; as well as 5) suppressing the release of IL-1 or the binding of IL-1 to its 
receptors to aid in attenuating fever.1,5,23  The most important effects of glucocorticoids on different 
cell types can be found in Table 1.2.18,23-26   
Table 1.2: Glucocorticoid effects on primary and secondary immune cells27 
Monocytes/macrophages 
↓ Number of circulating cells (↓ myelopoiesis, ↓ release) 
↓ Expression of MHC class II molecules and Fc receptors 
↓ Synthesis of pro-inflammatory cytokines (e.g. IL-2, IL-6, TNFα) and prostaglandins 
T cells 
↓ Number of circulating cells (redistribution effects) 
↓ Production and action of IL-2 (most important) 
Granulocytes 
↓ Number of eosinophils and basophil granulocytes 
↑ Number of circulating neutrophils 
Endothelial cells 
↓ Vessel permeability 
↓ Expression of adhesion molecules 
↓ Production of IL-1 and prostaglandins 
Fibroblasts 
↓ Proliferation 
↓ Production of fibronectin and prostaglandins 
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It has been a long accepted theory that glucocorticoids exert their anti-inflammatory properties by 
inhibiting the action of phospholipase A2.  This theory was challenged by Lane et al, which 
monitored the anti-inflammatory effects of systemic dexamethasone on exudate concentrations of the 
eicosanoids prostaglandin E2, thromboxane B2, 6-keto-PGF1α, and leukotriene B4.
28  In their study, 
dexamethasone revealed no significant suppression of exudate concentrations of the previously 
mentioned eiconsanoids.28  Therefore, it was concluded that the primary anti-inflammatory property 
of glucocorticoids was not through the inhibition of phospholipase A2.
28  Even though that study 
failed to demonstrate suppression of eicosanoids in exudate, associated with the administration of 
dexamethasone, it was shown that prostaglandin, arachidonic acid, and other inflammatory mediators 
were inhibited by glucocorticoids.29,30  Current understanding of glucocorticoids divides their actions 
into classical genomic effects and non-genomic effects.12,18,19,29,30   
The classical genomic properties are mediated by the cytosolic glucocorticoid receptor 
(GCR), a 94-kD protein.  The GCR exists as a multiprotein complex with a variety of heat shock 
proteins, such as Hsp90, Hsp70, Hsp56, and Hsp40.18  The GCR also has interaction with 
immunophilins, (co)chaperones, and kinases of the mitogen-activated protein kinase (MAPK) 
signaling system.18  The GCR is comprised of three different domains with a variety of functions: an 
N-terminal domain containing transactivation functions, a DNA-binding domain, and a ligand-
binding domain that consists of 12 α-helices and is involved in the formation of the hydrophobic 
ligand-binding pocket.18  Because of their lipophilic structure, glucocorticoids are able to easily enter 
the cytosol of the cell through passive diffusion.12,18  Glucocorticoids bind to the GCR resulting in 
activation of the GC/GCR receptor complex, with subsequent dissociation of the (co)chaperones 
from the GC/GCR complex occurring.12,18  Within 20 minutes of the (co)chaperone dissociation the 
GC/GCR complex is translocated into the nucleus where it binds to glucocorticoid responsive 
elements (GREs).12,18,19  Once the GC/GCR has entered the nucleus gene transcription can be 
impacted.  The binding of the activated GC/GCR complex to positive GREs induces the synthesis of 
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anti-inflammatory proteins (lipocortin 1 and IκB).12,18,19  Conversely glucocorticoids can inhibit gene 
transcription via binding between GCR and negative GREs.  Down regulation of protein synthesis 
has been shown to suppress transcription of the inflammatory genes interleukin-1 and interleukin-
2.18,30  Glucocorticoids are also able to affect transcription of genes that do not contain GREs, and 
inhibit pro-inflammatory gene expression through transrepression.12,18,19,30  This property occurs 
when the GC/GCR complex interacts directly or indirectly with transcription factors such as activator 
protein 1 (AP1), nuclear factor- κB (NF-κB), or interferon regulatory factor-3 (IRF-3).12,18,19,30  These 
transcription factors are involved in regulating the expression of pro-inflammatory genes by reducing 
transcriptional activities resulting in anti-inflammatory and immunosuppressive effects.12,18,19,30  
Through this negative regulation, glucocorticoids prevent the translocation and function of pro-
inflammatory transcription factors, thus suppressing synthesis of inflammatory mediators such as IL-
1, IL-2, IL-6, IL-8, TNF-α, IFN-γ, and prostaglandins.12,18,19,30  The principle mechanism for this 
negative regulation is through the synthesis of IκB.12,18,19,30  Within the cytoplasm of inactive cells, 
NF-κB is bound to an IκB protein.12,19,30  When bound to NF-κB, IκB prevents the translocation of 
NF-κB into the nucleus.12,19,30  Once stimulated, IκB undergoes phosphorylation and degradation 
allowing NF-κB to enter the cell nucleus and interact with genes responsible for IL-1, IL-2, IL-6, IL-
8, TNF-α, IFN-γ, and prostaglandins.12,18,19,30  Mechanisms that do not involve GREs are also critical 
for controlling the pro-inflammatory cellular effects.  These mechanisms include 1) binding of the 
GCR to the p65 subunit of the NF-κB domain thus inhibiting the transcriptional activity of NF-κB; 2) 
inducing synthesis of IκB which chelates activated NF-κB and blocks transcriptional activity of NF-
κB; and 3) competition of coactivators between the GC/GCR complex and various transcription 
factors.12,18,30  The genomic effects of glucocorticoids usually take hours to days to become evident. 
Rapid clinical responses are commonly seen with glucocorticoid administration that cannot 
be explained by the classical, genomic mechanisms of glucocorticoids.  Therefore, several different 
non-genomic mechanisms have been hypothesized for these properties.  One suggested theory 
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involves non-specific glucocorticoid interactions with cellular membranes that alters the 
physiochemical properties and activities of membrane-bound proteins.  This mechanism results in 
decreased sodium and calcium transport across the plasma membranes of immune cells.18,29  
Subsequently this is believed to result in rapid immunosuppression and a decrease in the 
inflammatory process.18,29   Another hypothesis that may explain the rapid effects of glucocorticoids 
is that glucocorticoids bind to GCRs and not only result in classical genomic effects, but also rapid 
non-genomic effects.  The underlying theory is that release of arachidonic acid from cell membrane-
associated phospholipids is regulated by mediators which includes growth factors, adaptor proteins, 
MAPK, phospholipase A2, and lipocortin 1.18,29  It has been shown that dexamethasone can inhibit 
the release of arachidonic acid subsequent to phospholipase A2 activation through a GCR-dependent, 
but a transcription-independent mechanism.18,29  The final hypothesis that may justify non-genomic 
glucocorticoids effects on immune cells involves the presence of a membrane-bound GCR which is a 
variant of the cytosolic GCR associated with genomic effects.18,29  It has been shown that 
immunostimulation increases the percentage of membrane-bound GCR which may indicate that they 
play a role in chronic inflammatory disease.18,29  Regardless of the mechanism, rapid non-genomic 
properties play an essential role in the control of inflammation and immunosuppression. 
Side Effects of Glucocorticoids 
Systemic glucocorticoid administration in the equine host has been associated with adverse 
side effects such as hypothalamic-pituitary-adrenal axis suppression, muscle wasting, hyperglycemia, 
polyuria, polydipsia, immunosuppression, and laminitis.15,17,31,32  Adrenocortical dysfunction can be 
monitored through endogenous cortisol response to ACTH administration.  Multiple studies have 
investigated the horse’s adrenocortical function in response to exogenous glucocorticoids.  Cortisol 
suppression, indicating adrenal suppression, occurs following intravenous, intramuscular, and 
aerosolized formulations of glucocorticoids.13,21,31-34  It appears that short-term parenteral 
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administration of dexamethasone and prednisolone sodium succinate do not result in adrenocortical 
dysfunction as they are still responsive to ACTH stimulation testing.21,31,33,34  However, a single dose 
of prednisolone acetate and triamcinolone has resulted in adrenocortical dysfunction for 14 to 21 
days.14,21,36,37  Anecdotal evidence suggests an association between glucocorticoids and equine 
laminitis, however a cause and effect relationship has yet to be demonstrated.  Despite the 
suggestion, the pathophysiology of equine laminitis in association with glucocorticoid administration 
is under investigation, but is beyond the scope of this thesis.15,17 
Cortisol Secretion 
Regulation of Cortisol Secretion 
Cortisol secretion from the adrenal cortex is mediated by ACTH released from the anterior 
pituitary.  Initially, corticotropin-releasing factor (CRF) is secreted from the hypothalamus, and is 
carried to the anterior pituitary via capillary plexus of the hypophysial portal system.  Upon binding 
of CRF to CRF receptors in the anterior pituitary ACTH secretion is stimulated.1,16  ACTH then acts 
upon the adrenocortical cells and activates adenylyl cyclase in the cellular membrane.  The activation 
of adenylyl cyclase stimulates cAMP formation within the cytoplasm.1,16  The formation of cAMP 
then results in the activation of intracellular enzymes essential for the production of adrenocortical 
hormones.1,16  It is the formation of cholesterol desmolase that is essential for the conversion of 
cholesterol to pregnenolone, which is the “rate-limiting” step in adrenocortical hormone 
production.1,16  The formation of CRF in the hypothalamus and the formation of ACTH in the 
anterior pituitary are controlled by a direct negative feedback of cortisol.1,16   
Circadian Rhythm of Cortisol Secretion 
The circadian rhythm of plasma glucocorticoid secretion has been documented in humans, 
rhesus monkeys, rats, dogs, mice, channel catfish, and swine.1,4,8,10  Some studies performed in the 
horse have been successful in identifying a circadian rhythm while others have not.   Hoffsis et al, 
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were unable to appreciate a consistent cortisol pattern in horses that underwent sampling at two and 
four hour intervals.7  However, a consistent pattern in the same horses was observed when sampling 
was performed at 28 hour intervals with concentrations peaking at approximately 8:00 am and 
reaching trough concentrations at approximately 4:00 pm.7  Because the half-life of cortisol is 
approximately 100 minutes, it was speculated that any effect venipuncture had on cortisol secretion 
would be minimal by 24 hours later.7  In that study, the effect of venipuncture and frequency of 
sample collection was believed to be responsible for diminishing the circadian rhythm.7  Another 
study performed by Bottoms et al, identified a rhythm in horses that underwent sample collection via 
venipuncture every two hours with peak and trough concentrations occurring at 8:00 am and 10:00 
pm, respectively.8  Toutain et al, performed hourly sample collection via jugular catheter to monitor 
cortisol secretion.9  Their analysis revealed an episodic pattern with intermittent peaks and troughs.9  
However, they did recognize a consistent peak at 6:00 am and trough concentrations from 9:00 pm to 
11:00 pm.9  Irvine et al, analyzed circadian rhythm in a variety of environments and management 
practices.10  They found untrained horses in their normal environment and trained race horses 
maintained in their normal environment and daily routine had peaks between 6:00 am to 9:00am, and 
troughs between 6:00 pm to 9:00 pm.10  Furthermore they found that the same untrained horses 
housed in a novel environment did not exhibit a circadian rhythm, and had a higher mean plasma 
cortisol concentrations when compared to those who exhibited a circadian rhythm.10  Findings from 
these studies strongly suggest that a circadian rhythm exists in horses, but is fragile and can be easily 
disrupted. 
Pharmacodynamic/Pharmacokinetic Modeling 
Pharmacodynamics of Glucocorticoids 
Pharmacodynamic studies have been performed including those evaluating the effect of 
glucocorticoids and adrenal gland function on leukocyte counts, plasma electrolyte concentrations, 
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cortisol secretion, pulmonary lung function, and cytologic evaluation of bronchoalveolar lavage 
(BAL) fluid.   Some of the earliest studies, dating back to 1948, focused on the effects of 
glucocorticoids on circulating eosinophils.7,11,25  Suppression of circulating eosinophils was 
determined to be an insensitive and unquantifiable tool for evaluating glucocorticoids effects on 
adrenal function.7,11,25  In addition to eosinophil response to glucocorticoids, evaluation of other 
leukocytes became the focus.  These studies revealed a significant leukocytosis and eosinopenia four 
hours after the administration of corticosteroids that lasted up to 17 hours.24,25  Furthermore, 
lymphopenia was also recognized for up to 16 hours following intramuscular dexamethasone 
administration.24,25  To further evaluate the effects of glucocorticoids on adrenal function, Eiler et al, 
monitored the effect corticosteroids had on plasma concentrations of sodium, potassium, calcium, 
and magnesium.25  Their work revealed that there was no significant effect on plasma sodium 
concentration, however there was significant elevations in calcium, magnesium, and potassium four 
hours after dexamethasone administration.25  They concluded that this was a direct effect of 
dexamethasone related to its  catabolic effects on muscle and bone.25  Various studies have evaluated 
the effects of corticosteroids on cortisol secretion.  Many of the early studies examined cortisol 
suppression in conjunction with leukocyte count and electrolyte concentrations following IM 
administration of dexamethasone.7,25  Hoffsis et al, administered dosages of dexamethasone ranging 
2-80 milligrams, and appreciated suppression of cortisol in all treatment groups.  Maximal 
suppression occurred between 12 and 24 hours, and returned back toward baseline by 72 hours for all 
treatment groups.7  Eiler et al, administered 20 milligrams of dexamethasone IM and monitored 
plasma cortisol concentrations for eight hours with maximal suppression occurring at approximately 
6 hours post dexamethasone administration.25  In that study they found maximal suppression of 
cortisol to be similar to the time of maximal change in electrolyte,leukocyte and eosinophil 
concentration.25  These studies were critical in establishing the effects that dexamethasone had on 
adrenal suppression in equine patients.  Studies subsequently began to compare the effects of 
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dexamethasone and other corticosteroids on adrenal suppression.  Toutain et al, evaluated the effects 
of dexamethasone alcohol, dexamethasone 21-isonicotinate, prednisolone 21-sodium succinate and 
prednisolone acetate on adrenal suppression.21  After IV administration of both dexamethasone 
formulations, plasma cortisol concentrations were significantly decreased from baseline two hours 
post-administration and remained suppressed for 72 hours.21  These findings were further supported 
by Soma et al, who found significant cortisol suppression from baseline beginning one hour 
following 0.05 mg/kg IV administration of dexamethasone that persisted for 72 hours.20  Following 
IM administration of both dexamethasone formulations similar results were seen, but cortisol 
remained suppressed until five days post-administration.21  With regards to prednisolone 21-sodium 
succinate, IV administration resulted in cortisol suppression 4 minutes post-administration, and IM 
administration resulted in suppression 9 minutes following administration.21  Cortisol concentrations 
returned to baseline values at 24 hours.  In contrast, the IM prednisolone acetate resulted in cortisol 
suppression at two hours, but remained suppressed until 21 days post-administration.21  Rush et al, 
compared aerosolized beclomethasone diproprionate and intravenous dexamethasone in horses with 
induced recurrent airway obstruction.22,32  Both the aerosolized beclomethasone and parenteral 
dexamethasone resulted in significant suppression of cortisol within two days of administration.22,32  
Cortisol concentrations returned to values similar to control horses two days after discontinuation of 
the beclomethasone and four days after discontinuing the dexamethasone.22,32  Cortisol suppression 
associated with the aerosolized beclomethasone was a surprising finding since human patients rarely 
experience the systemic effects of aerosolized beclomethasone.22,32  The observation of cortisol 
suppression in response to aerosolized beclomethasone indicated the equine host systemically 
absorbs aerosolized beclomethasone.  This may further indicate that horses have increased sensitivity 
to corticosteroids than human patients.  The mainstay of research today surrounds the therapeutic 
effects of corticosteroids for recurrent airway obstruction.  Multiple studies have evaluated the 
effects of dexamethasone, beclomethasone, and prednisone on pulmonary function and cytological 
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evaluation of BAL fluid.  Improved pulmonary function was observed when aerosolized 
beclomethasone, intravenous, intramuscular, and oral dexamethasone were administered.33,35,38-41  
Recently, DeLuca et al, observed reduced expression of IL-8, chemokine ligand 2 and IL-1β in 
bronchoalveolar lavage fluid following the administration of oral dexamethasone.41  The combination 
of improved pulmonary function and cortisol suppression following administration of synthetic 
corticosteroids provides support that adrenal suppression may approximately parallel the anti-
inflammatory effect and metabolic half-life.5,31  Prednisone administered orally has not been shown 
to have consistent beneficial effects for horses affected with recurrent airway obstruction.38,39,42  This 
is most likely due to decreased absorption of prednisone and decreased metabolism to the active drug 
prednisolone.38,39,42  Recently Soma et al, also evaluated the effects of dexamethasone on plasma 
glucose and lactate concentrations.20  Following IV dexamethasone administration, significant 
increases in lactate concentration and glucose were present between 4 and 60 hours, 8 and 36 hours, 
respectively.20  These changes highlight the influence glucocorticoids have on carbohydrate 
metabolism and subsequent gluconeogenesis.20 
Pharmacokinetics of Glucocorticoids 
Few pharmacokinetic studies have been performed in the equine host.  Utilizing HPLC with a 
level of sensitivity of 2 to 3 ng/ml, Toutain et al, was the first to describe pharmacokinetic parameters 
for dexamethasone in horses.21  In that study dexamethasone was detectable in plasma for up to 150 
to 180 minutes post administration, and a two-compartment open model with elimination from the 
central compartment best described the elimination of dexamethasone from plasma.21  In addition, 
the concentration of dexamethasone at time 0 (Cp
o) was 346.4 ng/ml for dexamethasone alcohol and 
301.25 ng/ml for dexamethasone 21-isonicotinate following a 0.05 mg/kg dose intravenously.21  
Complete pharmacokinetic parameters for IV dexamethasone alcohol and dexamethasone 21-
isonicotinate can be found in table 1.3. 
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Table 1.3: Mean pharmacokinetic parameters of dexamethasone following an IV 
bolus of dexamethasone alcohol or dexamethasone 21-isonicotinate21 
Pharmacokinetic Mean ± SD 
IV 
dexamethasone alcohol 
Mean ± SD 
IV 
Dexamethasone 21-isonicotinate 
A (ng/ml) 302 ± 83.8 251.8 ± 123.8 
B (ng/ml) 44.25 ± 8.8 49.4 ± 8.87 
α (min
-1
) 0.45 ± 0.12 0.48 ± 0.21 
β (min
-1
) 0.01 ± 0.005 0.01 ± 0.004  
k12 (min
-1
) 0.31 ± 0.11 0.33 ± 0.18 
k21 (min
-1
) 0.07 ± 0.006 0.09 ± 0.17 
kel (min
-1
) 0.09 ± 0.01 0.07 ± 0.03 
V’c (ml/kg) 151.3 ± 35.4 189.3 ± 66.8 
V’d(area) (ml/kg) 966 ± 192.6 906.5 ± 188.4 
ClB (ml/min*kg) 12.8  ± 2.25 12.3 ± 3.77 
t1/2(B) (min) 53.3 ± 14.0 53.6 ± 17.08 
 
In 1996, Cunningham et al, was the first to compare pharmacokinetic properties of intravenous 
dexamethasone to oral dexamethasone powder.43  Using radioimmunoassay with a sensitivity of 100 
pg/ml, maximum serum concentrations of dexamethasone were 23,200 pg/ml and 4,900 pg/ml 
following administration of 10 mg intravenously and 10 mg orally, respectively.43  The t1/2 was 
considerably longer in this study for both the IV administration (2.63 hours) and oral administration 
(4.36 hours) when compared to those in the Toutain study.21,43  Following both oral and IV 
administration, serum dexamethasone concentrations could be detected in the majority of horses at 
12 hours with a few having detectable levels at 24 hours.43  These findings are consistent with the 
improved sensitivity of the radioimmunoassay utilized.  The bioavailability for the oral 
dexamethasone powder was determined to be incomplete and variable (31%-88%) with a mean of 
61%.43  Complete pharmacokinetic parameters following  10 mg dexamethasone solution IV and 10 
mg dexamethasone powder orally can be seen in table 1.4. 
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Table 1.4: Mean pharmacokinetic parameters for IV and oral dexamethasone following  
a 10 mg dose  
Pharmacokinetic Dexamethasone 
10 mg IV 
Pharmacokinetic Dexamethasone Powder 
10 mg orally 
α (h
-1
) 3.15 ± 3.38   
β (h
-1
) 0.26 ± 0.11 β (h
-1
) 0.16 ± 0.05 
AUC (ng*h/ml) 47.9 ± 6.44 AUC (ng*h/ml) 29.09 ± 8.69 
Vc (L/kg) 0.99 ± 0.33 Cmax (pg/ml) 4900 ± 170 
Vss(L/kg) 1.73 ± 0.48 tmax (h) 1.3 ± 0.5 
Cl (L/h*kg) 0.48 ± 0.06 F 0.61 ± 0.19 
t1/2 (h) 2.63 ± 1.19 T1/2 (h) 4.36 ± 1.34 
 
Pharmacokinetic analysis of prednisolone revealed that oral tablets had a bioavailability of 65% and 
oral liquid to have a bioavailability of 56%.39  These findings in addition to Cunningham et al, have 
been the hallmark for oral bioavailability and oral dosing of glucocorticoids.33  Soma et al, utilized 
liquid chromatography interfaced with triple spray quadrupole quantum tandem mass spectrometry to 
completely quantify dexamethasone, cortisol, and cortisone following IV administration of 
dexamethasone.20  Plasma concentrations were estimated to be 65.6 ± 21.6 ng/ml at Cp
o .20  Because 
of the increased sensitivity they were able to determine a three compartment model best described the 
elimination of dexamethasone.20  Elimination half-lives for each compartment were 0.33 hours, 2.19 
hours and 10.7 hours, and dexamethasone was still detected in two of the six horses at 48 hours post-
administration.20  However, at 72 hours post-administration the plasma concentrations of 
dexamethasone were below the level of quantification (LOQ) for all horses.20  All of the 
pharmacokinetic studies have been beneficial in determining the pharmacological effects of 
dexamethasone, but it appears Soma et al, have provided a complete explanation of the 
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pharmacokinetics following IV administration.  Median pharmacokinetic parameters may be found in 
table 1.5. 
 
Table 1.5: Pharmacokinetic parameters of dexamethasone 
following 0.05 mg/kg IV administration 
Pharmacokinetic Median Range 
α (h
-1
) 2.25 1.52-4.24 
t1/2α (h) 0.33 0.22-0.57 
β (h
-1
) 0.32 0.26-0.37 
t1/2β (h) 2.19 2.12-2.66 
γ (h
-1
) 0.07 0.05-0.10 
t1/2γ (h) 10.7 6.8-13.4 
Cl (L/h*kg) 0.44 0.38-0.6 
AUC0
inf
 (ng*h/ml) 113.5 83.0-131.7 
 
Vd (L/kg) 2.1 1.6-3.1 
 
 Glucocorticoids have proven to be beneficial in a variety of conditions in the equine patient.  
Through extensive research the metabolic and anti-inflammatory properties and the mechanisms 
through which they work have been well documented.  Although limited information regarding the 
pharmacokinetic properties of glucocorticoids is available, increased investigation has been 
performed evaluating their pharmacodynamic properties.  However, further research needs to be 
performed to evaluate the anti-inflammatory effects of parenteral glucocorticoids in the equine host. 
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CHAPTER 2 – Pharmacokinetics and pharmacodynamics of 
oral dexamethasone in healthy horses 
 
Introduction 
Therapeutic immune suppression through the administration of steroidal anti-inflammatory 
medications is necessary for a variety of conditions in equine medicine.  Examples of such disease 
include, but are not limited to, recurrent airway obstruction (heaves), interstitial pneumonia, immune-
mediated disease, hypersensitivity reactions, and non-infectious inflammatory conditions such as 
inflammatory airway disease (IAD).  Therapy for these conditions typically involves intravenous 
systemic glucocorticoid therapy which is then modified to lower dose, orally administered 
medication.   Oral glucocorticoid administration is continued for several days to weeks depending on 
the condition.  Over a course of tapering dose therapy, medication is eventually discontinued.  
Although oral preparations of glucocorticoids are commercially produced, they may not be readily 
available, efficacious, or economically feasible.  An example involves the powdered formulation of 
dexamethasone; AziumTM powder, that is frequently difficult to obtain, and therefore a compounded 
formulation may be utilized.  Other preparations available for oral administration include prednisone 
and prednisolone, which are poorly absorbed or may be cost prohibitive for extended use, 
respectively.   Subsequently, a common practice of therapy among equine clinicians,is the use of oral 
administration of the injectable formulation of dexamethasone solution.  The administration of oral 
dexamethasone solution is performed off-label with very limited investigation into its 
pharmacological effects. 
Endogenous glucocorticoids enter the blood in a circadian rhythm after being produced by 
the adrenal cortex.1,2  It is well understood that glucocorticoids exert their immunosuppressive and 
anti-inflammatory properties by altering gene expression or gene repression through genomic 
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pathways of mRNA production by binding to glucocorticoid receptors within the cytoplasm of target 
cells.1,3-6  Due to the rapid effects of glucocorticoids, non-genomic pathways have recently been 
recognized to play an important role in the anti-inflammatory and immunosuppressive effects of 
glucocorticoids.  Non-genomic pathways play an integral role through the binding of glucocorticoids 
to membrane receptors that instantly stimulate second messengers and electrolyte transfer rather than 
mRNA production.5,7  Dexamethasone, an analogue of prednisolone, has a longer duration of activity 
and is 25 times more potent than endogenous cortisol.8   
Systemic glucocorticoid administration has been associated with adverse side effects such as 
hypothalamic-pituitary-adrenal axis suppression, muscle wasting, hyperglycemia, polyuria, 
polydipsia, immunosuppression, and laminitis.4,9-12  Adrenocortical dysfunction is monitored through 
endogenous cortisol response to ACTH administration.  Previous studies have investigated the 
horse’s adrenocortical function in response to exogenous glucocorticoids.  Cortisol suppression, 
indicating adrenal suppression, occurs following intravenous, intramuscular, and interestingly 
following formulations of inhaled glucocorticoids.13-16  Short-term parenteral administration of 
dexamethasone, prednisolone sodium succinate, and aerosolized beclomethasone diproprionate has 
not been associated with adrenocortical dysfunction evidenced by response to ACTH stimulation 
testing10,13-15  However, a single dose of prednisolone acetate and triamcinolone has resulted in 
adrenocortical dysfunction for 14 to 21 days.13,17-19 
To the authors’ knowledge, the pharmacokinetics and pharmacodynamics of oral 
dexamethasone solution have been incompletely determined in horses.    Pharmacokinetic studies for 
IM/IV dexamethasone and oral glucocorticoid administration in the form of AziumTM powder, 
prednisone, and prednisolone have all been reported.10,13,16,20-22  The standard of oral dosing of 
glucocorticoids has been based on the bioavailability of AziumTM powder and prednisolone which is 
reported to be approximately 61% for both when administered to horses.20,22  Multiple studies have 
shown oral prednisone to have limited efficacy in the horse.21-24  Nevertheless, practitioners continue 
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to utilize oral prednisone in select cases due to the perception that prednisone may have less serious 
side effects than dexamethasone.  Previous studies have proven the benefits of aerosolized 
glucocorticoids and orally administered dexamethasone solution.  Pulmonary function studies 
examining the efficacy of glucocorticoids in horses have been utilized to measure the effects of 
aerosolized, systemically administered, and orally administered glucocorticoids to relieve signs of 
recurrent airway obstruction.14,15,24-28  Cornelisse et al, performed the first study to evaluate the 
efficacy of oral administration of dexamethasone solution in horses with clinical disease of recurrent 
airway obstruction.14  This study showed improved lung function within 6 hours after administration 
with peak effect 24 hours following oral administration.14  The pharmacokinetic and 
pharmacodynamic effects of aerosolized glucocorticoids have been evaluated rather extensively, and 
compared to the systemic administration of dexamethasone.11,14,15,24-27  Although anecdotal 
experience and limited investigation support the use of injectable dexamethasone solution to be 
administered orally, the pharmacokinetic and pharmacodynamic effects of orally administered 
dexamethasone solution have not been extensively evaluated. 
Not only has oral dexamethasone solution been shown to be effective against inflammatory 
conditions it also provides an economical and convenient means for the administration of 
glucocorticoids.  Although there is limited investigation into the pharmacological effects of orally 
administered dexamethasone solution, veterinary clinicians increasingly utilize injectable 
dexamethasone solution orally.  The focus of our study was to determine the pharmacokinetics of 
oral dexamethasone solution compared to the intravenous administration of dexamethasone and the 
administration of oral dexamethasone powder in healthy horses.  In addition, pharmacodynamic 
effects were evaluated based upon systemic cortisol response to the different formulations of 
dexamethasone and route of administration. 
Materials and Methods 
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Animals—Six healthy adult horses were used in the study approved by the Animal Care and Use 
Committee at Kansas State University.  The horses (4 mares and 2 geldings) ranging from 13 to 27 
years of age included 5 Quarter Horses and 1 Dutch Warmblood.  Body weight of the horses ranged 
from 385-630 kg.  All horses were considered to be healthy based upon physical examination, 
complete blood count, and serum biochemistry. 
All horses were allowed free access to individual runs, except during the experimental 
period.  During the experimental period, all horses were maintained in individual stalls beginning 18 
hours prior to drug administration and throughout the duration of sample collection.  Throughout the 
study all horses had access to fresh water at all times.  They were fed their typical complete pelleted 
diet in two equal feedings and grass hay ad libitum, except when food was withheld starting 8 hours 
before to 3 hours following drug administration for the fasted phase of the study.  All horses were 
accustomed to handling and venipuncture.   
Drug Administration—In a randomized crossover block design, each horse received in a random 
order: 1) dexamethasone solution 0.05 mg/kg IV, 2) dexamethasone solution 0.05 mg/kg PO, and 3) 
dexamethasone powder 0.05 mg/kg PO all in the fed and fasted states.   
Treatment Fed/Fasted Route of 
Administration 
Type of 
Glucorticoid 
Placebo 
Administered 
1 Fed IV DXM solution oral molasses 
2 Fasted IV DXM solution oral molasses 
3 Fed Orally DXM solution IV 0.9% NaCl 
4 Fasted Orally DXM solution IV 0.9% NaCl 
5 Fed Orally DXM powder IV 0.9% NaCl 
6 Fasted Orally DXM powder IV 0.9% NaCl 
Table 2.1: Treatment groups for 0.05 mg/kg dose of dexamethasone with fed/fasted state, route of 
administration, type of dexamethasone, and type of placebo 
 
To monitor the effects of the study on normal circadian rhythm, 5 of the 6 horses served as controls 
and received no treatment.  To further minimize any effects of normal circadian rhythm, studies 
started at 8:00 am for all treatment groups.  Intravenous administration of dexamethasone solution 
was performed by the same investigator via venipuncture of the left jugular vein.  Oral administration 
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of dexamethasone solution and powder was performed by the same investigator via oral dosing 
syringe.  There was a minimum washout period of 2 weeks between drug treatments.  A 
commercially available injectable formulation of dexamethasone was used for IV and PO solution 
administration.  Due to the inability to obtain AziumTM powder, a compounded formulation of 
dexamethasone powder from a reputable equine compounding pharmacy was utilized mixed in liquid 
molasses for the PO powder administration.  When oral dexamethasone was administered an IV 
placebo was also administered consisting of 0.9% NaCl equivalent to a volume of 2 mg/ml 
dexamethasone at 0.05 mg/kg.  When IV dexamethasone was administered oral placebo consisted of 
liquid molasses equivalent to the calculated volume of oral dexamethasone solution or powder.   
Collection of samples and measurement of drug concentrations—Serial blood samples (10ml) 
were collected via a 14-gauge, 5.25-inch catheter inserted into the right jugular vein.  Prior to 
catheter placement, an area over the right jugular vein was clipped, aseptically prepared with 
chlorhexidine gluconate 4%, rinsed with 70% isopropyl alcohol, and the skin infiltrated with 2% 
lidocaine HCL.  Serial blood samples for the control group were taken every two hours for 48 hours.  
For the treatment groups, initial blood samples were collected 24 hours before drug administration, 
while still at their normal environment outside the hospital.  Serial blood samples were then collected 
before drug administration (time 0), 15, 30, 45 minutes and 1, 2, 4, 8, 12, 24, 36, 48, and 72 hours 
after drug administration.  Blood samples were immediately transferred to sodium heparin tubes and 
serum red top tubes.  Following centrifugation serum and plasma were frozen at -70˚C until analyzed 
for plasma dexamethasone and serum cortisol concentrations.  Plasma dexamethasone concentrations 
were analyzed via liquid chromatography-mass spectrometry with a minimum level of quantification 
of 1ng/ml.  Serum cortisol concentrations were analyzed with the use of chemiluminescent enzyme 
immunoassay with a limit of quantification of 5.5-1,380 nmol/L. 
Statistical analysis—Comparisons of pharmacokinetic parameters were performed for all treatment 
groups (intravenous dexamethasone, oral compounded powder, and oral dexamethasone solution 
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both in the fed and fasted state) via non-parametric Kruskall-Wallis one-way ANOVA.  When 
significant (P<0.05) differences were determined pairwise multiple comparison procedures were 
performed via Dunn’s method.  Comparisons of pharmacodynamic parameters (cortisol suppression) 
were performed for all treatment groups using the mixed procedure for repeated measures.  When 
significant (p<0.05) differences were determined pairwise multiple comparison procedures were 
performed via least square means.  Student t-test exercised at each time point was utilized to compare 
mean cortisol concentrations in the fed and fasted state for each treatment group.  To evaluate the 
circadian rhythm of cortisol secretion one-way ANOVA was utilized with Tukey Kramer HSD for 
multiple comparisons. 
Pharmacokinetic analysis—Plasma dexamethasone concentration versus time data for each animal 
was analyzed after each treatment through the use of a pharmacokinetic computer program* to 
estimate variables.  A noncompartmental model was used to calculate AUC0
∞, clearance, terminal 
half-life, and volume of distribution steady state for intravenous administration.  For oral 
administration a noncompartmental model was also utilized to calculate maximum plasma 
concentration, terminal half-life, and AUC in addition to other parameters.  The linear trapezoidal 
rule was utilized to determine AUC from time zero to infinity.  Clearance was calculated by the dose 
divided by AUC.  Volume of distribution steady state (Vdss) was calculated by the equation: Vdss = 
Dose * AUMC/AUC2.  The terminal half-life (t1/2) was calculated by the equation t1/2 = 0.693 /λz.  
For the PK-PD modeling, the calculated pharmacokinetic parameters were best described with a two 
compartmental model for IV administration with bolus input and first-order elimination.  A one 
compartmental model best described the oral administration treatment groups with first-order input 
and output with no lag time.  After IV administration, plasma concentration (C) of dexamethasone 
was described by the equation: C(t) = A-αt + B-βt where t is time after drug administration; A and B 
are the y-axis intercepts for the distribution and elimination phases of the curve, respectively, and α 
and β are the slopes for the distribution and elimination phase of the curve, respectively.  Plasma 
28 
concentration of dexamethasone after oral administration was described by the equation: C(t) = D * 
K01/V(K01-K10) * (e
-K
10
*t-e-K01
*t) where D is the dose of dexamethasone that the horse received, K01 is 
the rate constant for absorption, V is the volume of distribution for the central compartment, and K10 
is the rate constant for elimination.  The fraction of the dose absorbed  (%F) of dexamethasone 
solution and compounded powder after oral administration was calculated by the equation: %F 
=100%* AUCPO/AUCIV where AUCPO is the AUC following oral administration and AUCIV 
following IV administration.  The time to maximum plasma concentration (Tmax) and maximum 
plasma concentration (Cmax) of dexamethasone following oral administration were determined by 
actual measured data points. 
Pharmacodynamic analysis—Adrenal cortical suppression was analyzed via serum cortisol 
response to the methods of dexamethasone administration and formulation of dexamethasone.  
Actual cortisol response was analyzed by actual measured data points.  Predicted pharmacodynamic 
parameters were estimated by a pharmacokinetic-pharmacodynamic model using a sigmoid 
inhibitory effect model with a baseline effect parameter.  The equation for the sigmoid inhibitory 
effect model used was: E = Emax – (Emax-E0)[C
γ/(Cγ+ECγ50)] where Emax is the maximum 
suppression of cortisol, E0 is the cortisol concentration at time zero, C is the concentration of 
dexamethasone, γ is the shape parameter, and EC50 is the concentration of dexamethasone to 
produce 50% reduction of cortisol.  Predicted pharmacodynamic parameters analyzed included: Emax, 
ECe50, E0, and rate of drug loss from the effect compartment (Ke0). 
Results--Dexamethasone was tolerated well by all horses after both oral and IV administration.  No 
adverse effects were detected. 
Mean plasma dexamethasone concentrations over time following IV and oral administration 
of the different dexamethasone formulations were plotted (Figure 2.1 and 2.2) for both the fed and 
fasted states.  Plasma dexamethasone concentrations were below level of quantification (LOQ=1 
ng/mL) 12 hours following dexamethasone administration for all treatment groups except for the 
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fasted, oral solution which was below the LOQ at 8 hours post-administration.  Estimates of the 
pharmacokinetic and pharmacodynamic parameters for dexamethasone and cortisol for all treatment 
groups are shown in tables 2.1 and 2.2.  At time zero (C0) the estimated plasma dexamethasone 
concentration following IV administration was 73.92 and 66.34 ng/ml for the fed and fasted states, 
respectively.  Following oral administration, there was a significant difference in maximum 
measured plasma concentration of dexamethasone (Cmax) between the orally administered 
dexamethasone solution for both the fed and fasted (9.75 and 9.65 ng/ml) states compared to the 
compounded powder (23.18 ng/ml) in the fasted state.  However, there was no significant difference 
in the time (Tmax) which Cmax was achieved (0.79 hr – 1.50 hr).  Following IV administration, 
there was a significant difference between t1/2 for the fed and fasted state, 2.53 and 3.45 hours, 
respectively.  There was no significant difference between t1/2 for the oral dexamethasone solution or 
powder.  For the horses receiving dexamethasone administered by the IV route, the clearance was 
7.31 and 7.18 ml/min/kg for fed and fasted treatment groups, the Vdss was 1.27 and 1.69 L/kg for fed 
and fasted IV treatment groups, and the AUC0
inf
 was 116.50 and 120.36 hr*ng/mL for fed and fasted 
IV treatment groups.  The AUC0
inf
 for the orally administered dexamethasone solution was 43.28 and 
54.04 hr*ng/mL for the fed and fasted treatment groups.  There was a significant difference between 
AUC0
inf
 for the compounded powder treatment group of 41.19 and 79.47 for the fed and fasted 
groups, respectively.  The bioavailability for the orally administered dexamethasone solution was 
35% and 44% for the fed and fasted treatment groups, respectively.  For the orally administered 
compounded powder treatment group the bioavailability was 33% and 70% for the fed and fasted 
treatment group, respectively. 
Endogenous cortisol versus time plot for dexamethasone administration for all treatment 
groups is shown by figures 2.3 and 2.4.  There was no significant difference between cortisol 
suppression and treatment.  However, there was significant suppression in serum cortisol 
concentration from baseline concentration starting at 1 hour post-administration for all fasted 
30 
treatment groups that continued until 72 hours post-administration.  Likewise, there was significant 
suppression of serum cortisol concentration from baseline for all fed treatment groups starting at 2 
hours post-administration and continuing to 48 hours post-administration.  
Predicted pharmacodynamic parameters are shown in Table 3.  Modeling of the 
intravenously administered dexamethasone was best described by a two-compartment model  
with elimination from central compartment, as compared to one-compartment modeling for the orally 
administered treatment groups.  There was no significant difference between the different treatment 
groups and Emax, E0, and KEO.  However, the difference for ECe50 between oral dexamethasone 
solution in the fed state (0.28 ng/ml) was significantly different from the ECe50 of the IV fasted (0.95 
ng/ml) and IV fed (0.93 ng/ml) treatment groups.  Predicted cortisol response based upon the 
pharmacokinetic/pharmacodynamic model are represented in figures 2.5 and 2.6. 
Evaluation of endogenous cortisol for the presence of circadian rhythm revealed that there 
was diurnal variation.  Cortisol concentrations at 6:00 am and 8:00 am were significantly higher than 
those at 8:00 pm and 10:00 pm.  Similarly cortisol concentrations at 12:00 pm were significantly 
higher than cortisol concentrations at 10:00pm.  These results are represented in figure 2.7. 
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Figure 2.1: mean plasma dexamethasone concentration following 0.05 mg/kg IV and PO administration in the 
fasted state 
 
 
 
Dexamethasone 0.05 mg/kg to fed horses (n=6)
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Figure 2.2: mean plasma dexamethasone concentration following 0.05 mg/kg IV and PO administration in the fed 
state      
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Figure 2.3: Overall mean cortisol suppression for all fasted treatment groups following 0.05 mg/kg dose of 
dexamethasone (dashed bars significant from baseline: p<0.05)  
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Figure 2.4: Overall cortisol suppression for all fed treatment groups following 0.05 mg/kg dose of dexamethasone 
(dashed bars significant from baseline: p<0.05)
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Figure 2.5: Predicted cortisol response based upon pharmacokinetic/pharmacodynamic modeling 
following 0.05mg/kg dose of dexamethasone 
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Figure 2.6: Predicted cortisol response based upon pharmacokinetic/pharmacodynamic modeling 
Following 0.05 mg/kg dose of dexamethasone 
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Figure 2.7: Mean circadian rhythm of endogenous cortisol secretion 
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Discussion— Veterinarians are increasingly utilizing dexamethasone solution orally with limited 
information regarding its pharmacokinetic and pharmacodynamic properties.  This study was 
designed to determine the pharmacokinetics of oral dexamethasone in horses after receiving 
dexamethasone solution intravenously and orally, in addition to oral dexamethasone powder.  
Furthermore, pharmacodynamic properties were evaluated by assessing adrenal suppression through 
changes in endogenous cortisol concentrations.  The effect of feeding on the absorption of orally 
administered dexamethasone was evaluated by administering all treatments to all horses in both the 
fed and fasted state. 
  This present study did not assess adrenal gland function prior to commencing the study due 
to the apparent health of the horses, and lack of apparent clinical signs associated with  pituitary pars 
intermedia dysfunction.  However, when analyzing serum cortisol concentrations one of the horses in 
the study failed to suppress to levels of the other horses, and had consistently higher cortisol 
concentrations than the rest of the group.  This particular horse was later euthanized and diagnosed 
with pituitary pars intermedia dysfunction.  For completeness of the study, the plasma 
dexamethasone and serum cortisol concentrations were still factored into the pharmacokinetic and 
pharmacodynamic parameters.   
The circadian rhythm of plasma glucocorticoid concentrations has been documented in 
humans, rhesus monkeys, rats, dogs, mice, channel catfish, and swine.2,8,30,31  Some studies 
performed in the horse have been successful in identifying a circadian rhythm while others have 
not.2,31-34  In those studies that have not identified a consistent rhythm it appears that sampling 
method and subsequent stress on untrained horses has been associated with the lack of a circadian 
rhythm.2,34  In the studies that identified a circadian rhythm peak concentrations occurred between 
6:00 am and 9:00 am, however trough concentrations occurred between 4:00 pm and 11:00pm.2,31-33  
Much like previous studies, the horses in the present study maintained a circadian rhythm of cortisol 
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secretion during hospitalization.  However, it is important to recognize that they were trained to 
handling, venipuncture, and hospitalization.  We conclude that a circadian rhythm of cortisol 
secretion exists in horses with a peak in the morning and a trough in the evening, but is fragile and 
may easily be disrupted when placed in stressful situations.   The described investigation did not 
disrupt the natural rhythm in this group of horses. 
Until recently, pharmacokinetic and pharmacodynamic analysis of dexamethasone in the 
horse has been considered to be incomplete because of the lack of sensitivity of previous analytical 
methods.  However, in 2005, Soma et al., utilized liquid chromatography interfaced with triple spray 
quadruple quantum tandem mass spectrometry with a sensitivity of 100 pg/ml to evaluate the 
pharmacokinetic and pharmacodynamic effects of intravenous dexamethasone.16  Previous studies 
utilized less sensitive high pressure liquid chromatography or radioimmunoassays to determine the 
pharmacokinetics of dexamethasone.13,20  The study by Soma et al., was integral in providing 
complete pharmacokinetic parameters following IV administration of dexamethasone.16  In 
comparison to previous studies which evaluated the pharmacokinetic parameters of IV 
dexamethasone, the pharmacokinetic results from our study (clearance, volume of distribution, mean 
residence time, AUC, C0) are similar to those found by Soma et al, as well as those found in the 
study by Cunningham et al.16,20  Therefore, the use of liquid chromatography-mass spectrometry with 
a minimum level of quantification of 1 ng/ml allowed us to accurately characterize the 
pharmacokinetic nature of dexamethasone.   
Our study is the first to evaluate the pharmacokinetics of oral dexamethasone solution in the 
horse.  Cunningham et al, provided the first oral pharmacokinetic study when they evaluated the 
pharmacokinetics of AziumTM powder.20  Peroni et al, then performed pharmacokinetic analysis of 
oral prednisolone several years later.22  These two studies have served as the benchmark for oral 
dosing of glucocorticoids with bioavailabilities of approximately 61% for both the AziumTM powder 
and prednisolone.20,22  The Tmax and the elimination t½ reported by Cunningham et al, (1.3 ± 0.5 hr 
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and 4.36 ± 1.34 hr) was similar to those in the present study for all oral treatment groups (ranging 
from 0.79 hr – 1.5 hr and 2.5 hr – 4.08 hr).20  For all oral dexamethasone treatment groups, the Cmax 
achieved in our study ranged from 9.75 ng/ml to 23.18 ng/ml as compared to 4.9 ng/ml for the 
AziumTM powder reported by Cunningham et al.20  Oral dexamethasone formulations in this study 
resulted in greater AUC0
inf
 (41.19 hr*ng/ml – 79.47 hr*ng/ml) compared to the results found by 
Cunningham et al, (29.09 ± 8.69 hr*ng/ml).20  Bioavailability in both studies was extremely variable 
ranging from 33% for the fed, compounded powder to 70% for the fasted, compounded powder in 
the present study.  Bioavailability for oral dexamethasone solution was 44% for the fasted solution 
and 35% for the fed solution.  Although there was no significant difference in bioavailability, the 
fasted compounded powder reached significantly higher maximum serum concentrations and had a 
much higher bioavailability of 70%.  The lack of significance in bioavailablility may be due to the 
extreme variability in oral absorption, and the limitations on the number of horses in the study. 
In the present study and previous studies, significant adrenal suppression as evidenced by 
suppression of cortisol concentrations from base-line was recognized starting 1-2 hours post 
administration of IV dexamtethasone.13,16  This suppression was preceded by slight increase in 
cortisol concentration at the first measured time point following dexamethasone administration.13,16  
It is possible that this could be associated with the administration of the medication, or it has been 
proposed that this may be associated with normal intra-circadian fluctuations with intermittent peaks 
and troughs.2,16,33  Horses in our study were catheterized and trained to handling and venipuncture, 
and care was taken to minimize excitement during administration of dexamethasone and during 
sample collection.  Cortisol suppression in the present study was similar to cortisol suppression found 
by Soma et al.16   For all the fasted treatment groups in our study, cortisol suppression was significant 
starting 1 hour following administration and remained significantly suppressed until 72 hours post-
administration which followed the same pattern found by Soma et al.16  In the fed treatment groups, 
cortisol suppression was significant starting at 2 hours until 48 hours.  Despite the fact that plasma 
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dexamethasone concentrations were not detected beyond 12 hours in our treatment groups, cortisol 
remained suppressed for 48 to 72 hours.  These findings in conjunction with the relatively high 
volume of distribution supports the idea that concentration at the cellular level is more important than 
plasma concentration.13,16  In addition, changes in transcription and translation may lag behind 
changes in drug concentration whether it is in the plasma, or at the glucocorticoid receptor. 
Because of the increased sensitivity of the analytical methods utilized by Soma et al, they 
were able to identify a third compartment that no other studies have identified.16  Due to the limit of 
quantification of the liquid chromatography-mass spectrometry used in the current study a two 
compartment model for the pharmacokinetic/pharmacodynamic modeling was identified.  It is 
speculated that the third compartment maintains effective dexamethasone concentrations and 
subsequently is responsible for the delayed recovery of serum cortisol concentrations.16  However, it 
is well understood that glucocorticoids exert their immunosuppressive and anti-inflammatory 
properties by altering gene expression or gene repression through genomic pathways of mRNA 
production by binding to glucocorticoid receptors within the cytoplasm of target cells.1,3-6  Due to the 
rapid effects of glucocorticoids, non-genomic pathways have recently been recognized to play an 
important role in the anti-inflammatory and immunosuppressive effects of glucocorticoids.  Non-
genomic pathways play an integral role through the binding of glucocorticoids to membrane 
receptors that instantly stimulate second messengers and electrolyte transfer rather than mRNA 
production.5,7   The genomic effects of glucocorticoids generally take hours to days to become 
evident.  It is still possible that the delayed recovery of serum cortisol concentration could be a result 
of the genomic effects and subsequent gene expression or gene repression. 
In the pharmacodynamic studies that have monitored the effects of glucocorticoids on 
pulmonary function in horses with recurrent airway obstruction some have also measured adrenal 
suppression through measuring cortisol concentrations.11,12,29,  In these studies cortisol suppression 
has corresponded with clinical improvement.  Rush et al, administered IV dexamethasone and 
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aerosolized beclomethasone diproprionate to horses with clinically induced recurrent airway 
obstruction.25,29  Significant suppression of cortisol was present at the first measured time point (2 
days) following parenteral dexamethasone and aerosolized beclomethasone administration.11,15,25,29,  
Significant improvement in pulmonary function was reported three days (the first measured time 
point) following glucocorticoid administration.11,15,25,29  The improved lung function was maintained 
one day following the last dose of aerosolized beclomethasone and three days following the last dose 
of IV dexamethsone.25,29  The pattern of improved lung function paralleled the suppression of 
endogenous cortisol.  Furthermore in the study by Cornelisse et al, IV dexamethasone resulted in 
significant improvement in lung function within 2 hours and reached a peak effect at 4-6 hours.14  In 
fasted horses, they found that oral dexamethasone solution resulted in improved lung function in 6 
hours with peak effect in 24 hours.14   However, it is important to note that a correlation between 
cortisol suppression and improved lung function is not necessarily a cause and effect or in this case 
truly a marker of immune effects, but changes were in parallel, suggestive it may be a surrogate 
marker, further studies are needed. 
Conclusion-- The pharmacokinetics measured in this study were similar to those previously reported.  
However, this was the first study to evaluate the pharmacokinetics of orally administered 
dexamethasone solution.  Our study effectively measured the pharmacokinetics of IV dexamethasone 
solution, oral dexamethasone solution and dexamethasone powder, and assessed the endogenous 
cortisol response.  Although the fasted, compounded powder achieved higher plasma concentrations 
and bioavailability, there was greater variability when compared to the oral solution.  In addition, 
cortisol suppression was similar among all treatment groups indicating similar pharmacodynamic 
response regardless of the plasma concentrations of dexamethasone.   
It has been suggested that it is possible to approximate the duration of therapeutic effects of 
synthetic and natural glucocorticoids by evaluating the hypothalamic pituitary-adrenal suppressive 
activity, and the degree of adrenal suppression corresponds with the drug’s anti-inflammatory 
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potency and metabolic half-life.10,13,35  Based on the findings in this study, it is possible that lower 
dosages or less frequent administration could have the same pharmacodynamic effects.  Therefore, 
future direction should include pharmacodynamic modeling utilizing reduced dosages.  The duration 
of cortisol suppression may also indicate that every other day dosing may be similarly effective as 
everyday dosing, and minimize the adverse side effects associated with glucocorticoid 
administration.  The pharmacokinetic/pharmacodynamic model described here in combination with 
other pharmacokinetic/pharmacodynamic models will be very useful in predicting pharmacodynamic 
effects and developing anti-inflammatory models for determining further dosing regimens.    
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